ARTICLE | Finance
Voucher equilibrium
Totting up supply, demand for Priority Review vouchers after Jazz-Spark deal
May 4, 2018 10:26 PM UTC
At $110 million, the sticker price on a Priority Review voucher from Spark Therapeutics Inc. (NASDAQ:ONCE) appears to be the new normal.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) purchased the voucher on April 30; Spark received it in December when FDA approved Luxturna voretigene neparvovec to treat biallelic retinal pigment epithelium-specific protein 65kDa (RPE65) mutation-associated retinal dystrophy...